Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 16/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 14/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407543 | 0.87 | DPP4 (0.48) | DPP4DPP8DPP9CYP1A2CYP3A4 | |
| SCHEMBL1408175 | 0.86 | DPP4 (0.43) | DPP4DPP8DPP9CYP1A2CYP3A4 | |
| SCHEMBL1407828 | 0.82 | DPP4 (0.43) | DPP4DPP8DPP9CYP1A2CYP3A4 | |
| SCHEMBL1408083 | 0.81 | DPP4 (0.55) | DPP4DPP8DPP9CNR1CNR2 | |
| SCHEMBL1407903 | 0.80 | DPP4 (0.47) | DPP4DPP8DPP9CYP1A2CYP3A4 | |
| SCHEMBL1408216 | 0.80 | DPP4 (0.47) | DPP4DPP8DPP9CYP1A2CYP3A4 | |
| SCHEMBL1408313 | 0.80 | DPP4 (0.49) | DPP4DPP8DPP9CYP1A2CYP3A4 | |
| SCHEMBL1407483 | 0.80 | DPP4 (0.56) | DPP4DPP8DPP9CNR1CNR2 | |
| SCHEMBL1408226 | 0.79 | DPP4 (0.69) | DPP4DPP8DPP9CNR1CNR2 | |
| SCHEMBL1408068 | 0.77 | DPP4 (0.71) | DPP4DPP8DPP9CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836206-B1 | AZOLOPYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2011-03-09 | — | — | EP | disclosed |
| EP-1836206-B1 | AZOLOPYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL MYERS SQUIBB CO (US) | 2011-03-09 | — | — | EP | disclosed |
| US-7635699-B2 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635699-B2 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635699-B2 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1836206-A1 | AZOLOPYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | Bristol-Myers Squibb Company (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20060178377-A1 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
| WO-2006071752-A1 | AZOLOPYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006071752-A1 | AZOLOPYRIMIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178377-A1 | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods | DPP4, DPP9, DPP3 | DPP4 1/4885DPP8 4/4885DPP9 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.